Abiopharma

🔍 Marcus David John (Executive)

Company: MARCUS CORP (MCS)

Report Date: 2026-08-07

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-07 | Code: H | shares_owned_after: 106,476.00
• Acquired 1,249 shares of Class B Common Stock (Derivative)
  Date: 2026-08-07 | Code: G | equity_swap_involved: false | shares_owned_after: 45,134.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Holds 253,650 shares of Class B Common Stock (Derivative)
  Date: 2026-08-07 | Code: H | shares_owned_after: 253,650.00 | Footnotes: F1, F2, F3, F4
• Holds 307,543 shares of Class B Common Stock (Derivative)
  Date: 2026-08-07 | Code: H | shares_owned_after: 307,543.00 | Footnotes: F1, F2, F3, F5

Footnotes:

• F1: This security is convertible into common stock on a 1-for-1 basis at no cost.
• F2: This security is immediately exercisable.
• F3: No expiration date.
• F4: Shares held by Matinee Fifteen Holdings, LLC and Matinee Fifteen Holdings 2 LLC.
• F5: As trustee of the SMDM 2012 Trust.